ClinicalTrials.gg
CompletedNCT07605741PeakAmyLUpdated Oct 28, 2026

Fast Cardiac Bone SPECT-CZT in Transthyretin Cardiac Amyloidosis

An observational study in Cardiac Amyloidosis, sponsored by Central Hospital, Nancy, France. Completed at 1 site in France. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

Updated Oct 28, 2026Now CompletedFirst site in France+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
200
Ages
18 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Amyloid Neuropathies, Familial with a site in France — 15 open to participants now, 16 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · France.

Enrollment
6th of 12
200 · median 175
Started
2026
with 2 others
Observational
12 of 35
9 open now
Registered
34th of 35
by date
Lead sponsor
2 of 35
Central Hospital, Nancy, France

Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, this one is the 6th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2026, is one of 12 observational ones, and was the 34th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

15 of the 35 studies in Amyloid Neuropathies, Familial with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 95 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Amyloid Neuropathies, Familial with a site in France, or all of them as a file.
02

Study summary

Transthyretin cardiac amyloidosis (ATTR-CA) is traditionally diagnosed using planar bone scintigraphy with a Perugini visual score ≥ 2. Fast cardiac CZT-SPECT will be evaluated for its ability to reproduce this classification and provide reproducible quantitative myocardial uptake metrics.

Read the detailed description

Transthyretin cardiac amyloidosis (ATTR-CA) has emerged as a major cause of infiltrative cardiomyopathy, and early diagnosis is associated with improved prognosis. ATTR is now recognized far more frequently than in the past, owing to increased clinical awareness and advances in non-invasive imaging strategies, including planar bone scintigraphy.

In the absence of monoclonal gammopathy, a Perugini grade ≥ 2 on planar bone scintigraphy constitutes a highly specific diagnostic criterion for ATTR-CA, obviating in most cases the need for endomyocardial biopsy. Consequently, planar bone scintigraphy acquired with conventional Anger cameras has become the reference method in this setting.

In recent years, full-ring cadmium-zinc-telluride (CZT) single-photon emission computed tomography (SPECT) whole-body cameras have rapidly emerged. These systems offer enhanced image quality and count sensitivity, mainly due to the high intrinsic detection efficiency of CZT detectors and a dedicated full-ring geometry that optimizes photon collection over the patient's body or specific organs of interest. They have enabled the development of ultrafast three-dimensional acquisitions combined with SUV-based image scaling, thereby improving patient comfort and throughput, while also allowing lesion quantification.

However, the ability of rapid CZT-SPECT/CT acquisitions to accurately replicate the ATTR-CA diagnostic information obtained from standard planar imaging remains insufficiently documented. Furthermore, although CZT-SPECT/CT technology allows for precise quantification, it has not yet been established whether Standard Uptake Value (SUV) based parameters can serve as reliable and reproducible imaging biomarkers for ATTR-CA Therefore, the aim of this retrospective study will be to (i) evaluate whether fast CZT-SPECT recordings can reproduce the diagnosis of ATTR-CA obtained using Perugini scoring on standard planar images, either by applying Perugini scoring to planar projections or by using quantitative parameters, and (ii) compare the reproducibility of these approaches.

03

Conditions studied

  • Cardiac Amyloidosis

Keywords

  • Cardiac amyloidosis, Bone scans, CZT, SPECT-CT, Perugini
04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Retrospectively enrolled patients routinely referred for bone scintigraphy for suspected transthyretin cardiac amyloidosis (ATTR-CA) . During this period, a rapid three-dimensional CZT-SPECT cardiac acquisition was systematically attempted in addition to conventional planar imaging, depending on camera availability, for diagnostic purposes, particularly for identifying blood-pool activity and other extracardiac confounding uptake areas

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who were routinely referred for bone scintigraphy for suspected transthyretin cardiac amyloidosis (ATTR-CA) between April 2024 and April 2025.

Exclusion criteria

Exclusion Criteria:

  • Patients who object to the use of their data
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
200 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients referred for bone scintigraphy for suspected ATTR-CA

    Patients referred for bone scintigraphy for suspected ATTR-CA underwent a fast cardiac CZT-SPECT acquisition followed by standard whole-body planar imaging three or four hours after 99mTc-HMDP injection

    Other: bone scintigraphy

Interventions

  • Otherbone scintigraphy

    Fast CZT camera bone scintigraphy and bone scintigraphy with conventional camera (standard care)

06

What researchers measure

Primary outcomes

  1. to evaluate whether fast CZT-SPECT recordings can reproduce the diagnosis of ATTR-CA obtained using Perugini scoring on standard planar images, either by applying Perugini scoring to planar projections or by using quantitative parameters

    Comparison between Perugini score obtained on the bone scan scintigraphy performed with CZT SPECT and performed with conventional camera

    Time frame: one day

07

Study locations

1 site
  • Chru Nancy
    Vandœuvre-lès-Nancy, 54511, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2026 to primary completion in Jul 2026, 1 month.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start May 2026 → Jun 2026, primary completion Jun 2026 → Jul 2026 and completion Jul 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 26, 2026
StartActual
Jun 30, 2026was May 2026
Primary completionActual
Jul 30, 2026was Jun 2026
CompletionActual
Sep 30, 2026was Jul 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 28, 2026
Sites
1 site added — first site in France
Show site
  • Chru Nancy · Vandœuvre-lès-Nancy, France
Oct 28, 2026
Start date
May 30, 2026→Jun 30, 2026 (actual)
Oct 28, 2026
Primary completion
Jun 30, 2026→Jul 30, 2026 (actual)
Oct 28, 2026
Study completion
Jul 30, 2026→Sep 30, 2026 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Completed
    1 site added — first site in France
    Show site
    • Chru Nancy · Vandœuvre-lès-Nancy, France
    Start date May 30, 2026→Jun 30, 2026 (now actual)
    Primary completion Jun 30, 2026→Jul 30, 2026 (now actual)
    Study completion Jul 30, 2026→Sep 30, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07605741
Responsible party
Pierre Yves MARIE (Prinicipal Investigator, Central Hospital, Nancy, France) — Principal investigator
First posted
May 26, 2026
Start date
Jun 30, 2026
Primary completion
Jul 30, 2026
Completion
Sep 30, 2026
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion